PBS
What’s in the 2022-23 Federal Budget for the eye health sector?
The Federal Government has laid out a $132 billion health agenda for the coming year – if it regains power ...
Beovu AMD therapy now listed on the PBS
Almost 13,000 Australians could save thousands annually with the Pharmaceutical Benefits Scheme (PBS) listing of Beovu (brolucizumab) for neovascular age-related ...
Novartis secures PBS recommendation for Beovu
An independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related ...
Anti-VEGF becomes most expensive drug on PBS
The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a ...
Brand names banished under new prescribing regulations
New regulations come into force from 1 February requiring doctors to prescribe PBS drugs by their active ingredient instead of ...
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to ...
Dry eye treatment in Australia
Dry eye remains a very common presentation to primary eyecare practitioners in Australia. Many experienced practitioners feel that the incidence ...
Anti-inflammatory eye drops added to PBS for Indigenous patients
Prednefrin Forte eye drops can now be prescribed to Aboriginal and Torres Strait Islander patients under the Pharmaceutical Benefits Scheme ...
Jetrea eye injection receives new PBS listing
A new formulation of the Jetrea intravitreal injection has been listed on Pharmaceutical Benefits Scheme (PBS), replacing the current powder ...